Ovid Therapeutics (OVID) Stock Forecast & Price Target

Ovid Therapeutics is viewed positively because OV329 targets a clinically validated GABA-AT mechanism while materially improving on vigabatrin’s core weakness, with mg-scale dosing, clean ophthalmology findings in 68 healthy volunteers, and stronger cortical inhibition at 400-600× lower dose. The setup is further strengthened by a pipeline that extends into TSC, infantile spasms, and broader DEEs, where even capped historical products like Sabril reached about $320M in U.S. sales and the company models roughly $1.9B of combined U.S. opportunity if OV329 succeeds. With about $170M in cash, a market cap around $475M, runway into 2029, and multiple catalysts over the next 12-15 months, the shares appear to underappreciate both the lead asset and OV4071 optionality.

Ovid Therapeutics is a speculative, cash-rich but fundamentally fragile biopharma story whose apparent valuation rests on highly uncertain pipeline outcomes rather than proven commercial execution. Its core epilepsy franchise still depends on achieving meaningful penetration in a ~630K addressable focal-onset market and converting ~30-40% drug-resistant patients, while the model itself assigns only 30% and 10% approval probabilities to OV329 and OV888, and carries OV4071 at nil in the bear case. Despite ~$170M cash as of Q2 2026 and a runway into 2029, the investment case is burdened by clinical, regulatory, safety, and dilution risks, and even the bear outcome leaves only ~$0.58 of FY27 net cash and exercise proceeds.